Method for diagnosing an adenocarcinoma or a benign prostate pathology
CA 2336174 C · Owner: Jolivet, Michel · Inventors: Tournel, Carole; Jolivet, Michel; Charrier, Jean-Philippe
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns a method for diagnosing a prostate adenocarcinoma in a male human patient without performing prostatic biopsy using the PSA protein (prostate specific antigen) present in the patient's blood serum, urine or seminal liquid. The method consists in: a) measuring the free PSA total level that is cleaved or non-cleaved; b) measuring the level of all or part of the cleaved free PSA; c) calculating the proportion of cleaved free PSA relative to the total free PSA; and d) diagnosing that the patient suffers from: a prostate adenocarcinoma when said ratio is not more than a reference value; a benign prostate pathology such as benign prostatic hypretrophy, when said ratio is …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 5, 1999 and granted May 15, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 5, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 5, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.